EvlaBio, a life sciences startup developing therapies for Left Ventricular Hypertrophy (LVH) in the context of Chronic Kidney Disease (CKD), has raised EUR 21 million in its seed financing round. The financing round was led by the French VC firm Kurma Partners, with AdBio Partners (Paris, Barcelona), Boehringer Ingelheim Venture Fund, NRW.Venture (NRW.Bank) and High-Tech Gründerfonds as co-investors. It is one of the largest financing rounds of its kind in the DACH region in recent years.
Advestra acted as Swiss legal counsel to EvlaBio. The team included Alexander von Jeinsen, Daniel Raun, Anna Capaul and Fabian Loretan (all Corporate M&A).